Effect of Lycopene Supplementation on Some Cardiovascular Risk Factors and Markers of Endothelial Function in Iranian Patients with Ischemic Heart Failure: A Randomized Clinical Trial.

IF 1.8 4区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Cardiology Research and Practice Pub Date : 2022-10-28 eCollection Date: 2022-01-01 DOI:10.1155/2022/2610145

Bahareh Karimian, Azam Soleimani, Ghasem Mohammadsharifi, Kiyan Heshmat-Ghahdarijani, Laila Rejali, Davood Shafie, Atefeh Amerizadeh, Masoumeh Sadeghi

{"title":"Effect of Lycopene Supplementation on Some Cardiovascular Risk Factors and Markers of Endothelial Function in Iranian Patients with Ischemic Heart Failure: A Randomized Clinical Trial.","authors":"Bahareh Karimian, Azam Soleimani, Ghasem Mohammadsharifi, Kiyan Heshmat-Ghahdarijani, Laila Rejali, Davood Shafie, Atefeh Amerizadeh, Masoumeh Sadeghi","doi":"10.1155/2022/2610145","DOIUrl":null,"url":null,"abstract":"Aim: This study aimed to explore if supplementary lycopene tablets may help heart failure (HF) patients improve their lipid profile, BP, and the flow-mediated dilation (FMD) index for endothelial function.Methods: Fifty patients with ischemic HF with a reduced ejection fraction (HFrEF) were randomly assigned to one of two groups: the lycopene group which received 25 mg lycopene tablets once a day for 8 weeks and the control group which received placebo tablets containing starch once a day for 8 weeks.Results: Our results showed that after two months, the amount of triglyceride (TG) and FMD improved significantly compared to the control, TG decreased (219.27 vs. 234.24), and the mean of FMD increased (5.68 vs. 2.95). Other variables, including total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density cholesterol (HDL-C), systolic blood pressure (SBP), and diastolic blood pressure (DBP), showed no improvement. Also, only SBP and FMD showed intragroup improvement in the intervention group. In the intervention group, only SBP and FMD exhibited intragroup improvement.Conclusions: It can be concluded that supplementing with lycopene can enhance endothelial function and reduce the TG levels in ischemic HFrEF patients. However, it had no positive effect on BP, TC, LDL-C, or HDL-C. Trial Registration. This clinical trial was registered at the Iranian Registry of Clinical Trials with IRCT registration number: IRCT20210614051574N4.","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2022-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635958/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiology Research and Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2022/2610145","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: This study aimed to explore if supplementary lycopene tablets may help heart failure (HF) patients improve their lipid profile, BP, and the flow-mediated dilation (FMD) index for endothelial function.

Methods: Fifty patients with ischemic HF with a reduced ejection fraction (HFrEF) were randomly assigned to one of two groups: the lycopene group which received 25 mg lycopene tablets once a day for 8 weeks and the control group which received placebo tablets containing starch once a day for 8 weeks.

Results: Our results showed that after two months, the amount of triglyceride (TG) and FMD improved significantly compared to the control, TG decreased (219.27 vs. 234.24), and the mean of FMD increased (5.68 vs. 2.95). Other variables, including total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density cholesterol (HDL-C), systolic blood pressure (SBP), and diastolic blood pressure (DBP), showed no improvement. Also, only SBP and FMD showed intragroup improvement in the intervention group. In the intervention group, only SBP and FMD exhibited intragroup improvement.

Conclusions: It can be concluded that supplementing with lycopene can enhance endothelial function and reduce the TG levels in ischemic HFrEF patients. However, it had no positive effect on BP, TC, LDL-C, or HDL-C. Trial Registration. This clinical trial was registered at the Iranian Registry of Clinical Trials with IRCT registration number: IRCT20210614051574N4.

Abstract Image

查看原文本刊更多论文

补充番茄红素对伊朗缺血性心力衰竭患者心血管危险因素和内皮功能指标的影响:一项随机临床试验

目的:本研究旨在探讨补充番茄红素片是否有助于心力衰竭(HF)患者改善血脂、血压和内皮功能的血流介导扩张(FMD)指数。方法:50例缺血性心力衰竭伴射血分数降低(HFrEF)患者随机分为两组:番茄红素组给予25 mg番茄红素片，每天1次，连续8周;对照组给予含淀粉的安慰剂片，每天1次，连续8周。结果:我们的研究结果显示，两个月后，与对照组相比，甘油三酯(TG)和FMD的含量明显改善，TG降低(219.27比234.24)，FMD的平均值增加(5.68比2.95)。其他变量，包括总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度胆固醇(HDL-C)、收缩压(SBP)和舒张压(DBP)均无改善。干预组只有收缩压和FMD有组内改善。在干预组中，只有收缩压和FMD表现出组内改善。结论:在缺血性HFrEF患者中，补充番茄红素可增强内皮功能，降低TG水平。然而，它对血压、TC、LDL-C或HDL-C没有积极影响。试验注册。该临床试验已在伊朗临床试验注册中心注册，IRCT注册号:IRCT20210614051574N4。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cardiology Research and Practice Medicine-Cardiology and Cardiovascular Medicine

CiteScore

4.40

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Cardiology Research and Practice is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies that focus on the diagnosis and treatment of cardiovascular disease. The journal welcomes submissions related to systemic hypertension, arrhythmia, congestive heart failure, valvular heart disease, vascular disease, congenital heart disease, and cardiomyopathy.